2022
DOI: 10.1093/noajnl/vdac167.053
|View full text |Cite
|
Sign up to set email alerts
|

MPC-1 Immunohistological Comprehensive Analysis of Angiogenic Factors Other Than Vegf in Glioblastomas in Relation to the Use of Bevacizumab

Abstract: To date, few clinical observations have been reported for changes of alternative angiogenic factors (other than vascular endothelial growth factor [VEGF]) in human gliomas under bevacizumab (Bev). The elucidation of the mechanism of action and resistance is imperative to overcome resistance to Bev and develop a more effective therapy. This study aims to investigate the status and change of alternative angiogenic factors regarding Bev usage.The present study used 56 glioblastoma tissues obtained at 3 different … Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles